glp-1 vials Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity one vial will last 8 Lilly lowers self-pay prices of
Description
The supplements independent effectiveness without lifestyle changes is unclear
The manufacturer of Victoza added 3 patents after paragraph IV certification, while the manufacturer of Saxenda added 1 patent (eTable 2)
Drinking plenty of water throughout the day is also key to staying hydrated and supporting digestion
Additionally, the single-center characterization of this trial can be considered a limitation of this study, which decreases its generalizability
Exposure: GLP-1RA initiation (liraglutide, semaglutide, tirzepatide)
